Overall, our data on circulating IL6 and CXCL10 expression were consistent with previous observations in CRC patients, whereas we were the first to demonstrate a correlation between plasma levels of either SCGF-β or CTACK and CRC patient clinical outcome. The gene discussed is IL6; the disease is colorectal carcinoma.